Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Infectious Diseases journal rankings 2025
258 ranked journals · Subfield in Medicine
Infectious Diseases has 258 ranked journals in 2025. The median OJR rose 0.05 on 2024 to 0.75, below the world average of 1.00; Q1 starts at OJR 1.19. The three highest-scoring journals with stable ranks are New England Journal of Medicine, Clinical Microbiology Reviews, and MMWR Morbidity and Mortality Weekly Report: each is likely ranked within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
Show all 42 subfields
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
258 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #1 of 258New England Journal of MedicineMassachusetts Medical Society · United States | 12.85Q1 | 34.58 2.47 up from 2024 | 2,504 | 16% | — | ||
Rank 2; likely between #2 and #2 of 258Clinical Microbiology ReviewsAmerican Society for Microbiology · United States | 9.01Q1 | 21.99 0.70 down from 2024 | 108 | 100% | — | ||
Rank 3; likely between #3 and #3 of 258MMWR Morbidity and Mortality Weekly ReportOACenters for Disease Control and Prevention · United States | 5.97Q1 | 16.46 1.77 down from 2024 | 713 | 100% | — | Falling vs field, 2022–25 | |
Rank 4; likely between #4 and #7 of 258The Lancet Global HealthOAElsevier BV · Netherlands | 4.51Q1 | 10.46 1.30 up from 2024 | 998 | 100% | $6,680 | ||
Rank 5; likely between #4 and #7 of 258The Lancet Infectious DiseasesElsevier BV · Netherlands | 4.32Q1 | 12.62 0.02 down from 2024 | 1,035 | 36% | $7,280 | ||
Rank 6; likely between #5 and #9 of 258EClinicalMedicineOAElsevier BV · Netherlands | 3.85Q1 | 13.02 2.06 up from 2024 | 1,672 | 100% | $5,780 | Rising vs field, 2022–25 | |
Rank 7; likely between #5 and #10 of 258The Lancet Regional Health - EuropeOAElsevier BV · United Kingdom | 3.64Q1 | 10.01 1.42 up from 2024 | 767 | 100% | $4,930 | ||
Rank 8; likely between #5 and #10 of 258PLoS MedicineOAPublic Library of Science · United States | 3.63Q1 | 9.79 0.63 down from 2024 | 536 | 100% | $6,460 | ||
Rank 9; likely between #6 and #10 of 258The Lancet MicrobeOAElsevier BV · United Kingdom | 3.54Q1 | 11.62 1.25 up from 2024 | 543 | 100% | $7,280 | ||
Rank 10; likely between #9 and #13 of 258Annals of Internal MedicineAmerican College of Physicians · United States | 2.94Q1 | 7.86 0.18 down from 2024 | 919 | 9% | — | ||
Rank 11; likely between #9 and #17 of 258The Lancet HIVElsevier BV · Netherlands | 2.82Q1 | 7.14 0.68 up from 2024 | 406 | 34% | $7,280 | Rising vs field, 2022–25 | |
Rank 12; likely between #10 and #18 of 258Communications MedicineOANature Portfolio · United Kingdom | 2.61Q1 | 8.29 1.01 up from 2024 | 607 | 100% | $3,690 | ||
Rank 13; likely between #11 and #18 of 258npj VaccinesOANature Portfolio · United Kingdom | 2.57Q1 | 7.58 0.55 up from 2024 | 588 | 100% | $3,890 | ||
Rank 14; likely between #11 and #18 of 258Emerging Microbes & InfectionsOATaylor & Francis · United Kingdom | 2.48Q1 | 6.80 0.40 down from 2024 | 805 | 100% | $2,643 | ||
Rank 15; likely between #11 and #18 of 258EurosurveillanceOAEuropean Centre for Disease Prevention and Control · Sweden | 2.44Q1 | 7.43 0.51 down from 2024 | 656 | 100% | — | ||
Rank 16; likely between #9 and #51 of 258Health care scienceOAPublisher not listed | 2.34Q1 | 7.40 3.46 up from 2024 | 103 | 100% | $2,300 | ||
Rank 17; likely between #13 and #23 of 258VirulenceOATaylor & Francis · United States | 2.22Q1 | 6.44 1.04 up from 2024 | 401 | 100% | $2,557 | Rising vs field, 2022–25 | |
Rank 18; likely between #15 and #21 of 258Clinical Infectious DiseasesOxford University Press · United States | 2.19Q1 | 6.63 0.15 up from 2024 | 2,165 | 63% | $4,763 | Rising vs field, 2022–25 | |
Rank 19; likely between #11 and #71 of 258Oxford Open ImmunologyOAOxford University Press · United Kingdom | 1.98Q1 | 7.22 2.69 up from 2024 | 33 | 100% | $2,331 | ||
Rank 20; likely between #6 and #122 of 258European Journal of Microbiology and ImmunologyOAAkadémiai Kiadó · Hungary | 1.97Q1 | 4.97 1.77 up from 2024 | 70 | 100% | — | ||
Rank 21; likely between #16 and #33 of 258Current HIV/AIDS ReportsSpringer Science+Business Media · United States | 1.94Q1 | 4.93 0.19 down from 2024 | 124 | 68% | $4,190 | Rising vs field, 2022–25 | |
Rank 22; likely between #18 and #28 of 258Emerging infectious diseasesOACenters for Disease Control and Prevention · United States | 1.91Q1 | 5.27 0.43 up from 2024 | 1,545 | 100% | — | ||
Rank 23; likely between #17 and #38 of 258BMC Global and Public HealthOAPublisher not listed | 1.89Q1 | 4.12 1.05 up from 2024 | 111 | 100% | $2,490 | ||
Rank 24; likely between #19 and #35 of 258Infectious Diseases and TherapyOAAdis, Springer Healthcare · United Kingdom | 1.83Q1 | 5.70 0.08 down from 2024 | 461 | 100% | $7,400 | Rising vs field, 2022–25 | |
Rank 25; likely between #19 and #34 of 258The Lancet Regional Health - Southeast AsiaOAPublisher not listed | 1.83Q1 | 4.51 0.02 down from 2024 | 467 | 100% | $2,250 | ||
Rank 26; likely between #21 and #35 of 258JMIR Public Health and SurveillanceOAJMIR Publications · Canada | 1.76Q1 | 4.52 0.10 up from 2024 | 829 | 100% | $2,800 | Falling vs field, 2022–25 | |
Rank 27; likely between #22 and #37 of 258Journal of the International AIDS SocietyOAInternational AIDS Society · United States | 1.71Q1 | 4.24 0.23 down from 2024 | 466 | 100% | $2,600 | Rising vs field, 2022–25 | |
Rank 28; likely between #18 and #57 of 258hLifeOAElsevier BV | 1.70Q1 | 5.73 3.11 up from 2024 | 81 | 100% | $2,300 | ||
Rank 29; likely between #25 and #34 of 258PLoS PathogensOAPublic Library of Science · United States | 1.69Q1 | 5.13 0.14 down from 2024 | 1,949 | 100% | $3,043 | ||
Rank 30; likely between #23 and #41 of 258Journal of Clinical MicrobiologyOAAmerican Society for Microbiology · United States | 1.65Q1 | 4.88 0.37 up from 2024 | 624 | 100% | — | Rising vs field, 2022–25 | |
Rank 31; likely between #24 and #43 of 258Clinical Microbiology and InfectionElsevier BV · United Kingdom | 1.63Q1 | 5.49 0.30 up from 2024 | 1,000 | 67% | $3,780 | Falling vs field, 2022–25 | |
Rank 32; likely between #24 and #44 of 258Antimicrobial Resistance and Infection ControlOABioMed Central · United Kingdom | 1.62Q1 | 5.74 0.46 up from 2024 | 452 | 100% | $3,290 | ||
Rank 33; likely between #22 and #52 of 258Journal of Epidemiology and Global HealthOAElsevier BV · Netherlands | 1.59Q1 | 4.45 0.86 up from 2024 | 290 | 100% | $2,690 | ||
Rank 34; likely between #22 and #58 of 258npj VirusesOASpringer Science+Business Media | 1.58Q1 | 3.60 1.00 down from 2024 | 80 | 100% | $2,790 | ||
Rank 35; likely between #17 and #101 of 258Current Clinical Microbiology ReportsSpringer Science+Business Media · Germany | 1.57Q1 | 5.04 2.07 up from 2024 | 59 | 46% | $4,790 | ||
Rank 36; likely between #28 and #46 of 258Antiviral ResearchElsevier BV · Netherlands | 1.56Q1 | 4.34 0.01 down from 2024 | 544 | 55% | $4,160 | ||
Rank 37; likely between #24 and #58 of 258Reviews in Medical VirologyWiley · United Kingdom | 1.53Q1 | 6.03 1.40 down from 2024 | 257 | 44% | $4,880 | ||
Rank 38; likely between #28 and #53 of 258Journal of Infection and Public HealthOAElsevier BV · Netherlands | 1.51Q1 | 5.08 0.46 up from 2024 | 800 | 100% | $2,310 | ||
Rank 39; likely between #30 and #50 of 258The Journal of Infectious DiseasesOxford University Press · United States | 1.49Q1 | 3.92 0.42 down from 2024 | 1,674 | 72% | $4,763 | ||
Rank 40; likely between #20 and #85 of 258Infectious MedicineOAElsevier BV · China | 1.48Q1 | 4.20 0.99 up from 2024 | 132 | 100% | $2,500 | ||
Rank 41; likely between #34 and #49 of 258PLOS Global Public HealthOAPublic Library of Science · United States | 1.47Q1 | 3.29 0.18 up from 2024 | 2,808 | 100% | $2,496 | ||
Rank 42; likely between #32 and #56 of 258Virology JournalOABioMed Central · United Kingdom | 1.45Q1 | 4.19 0.18 down from 2024 | 849 | 100% | $3,290 | ||
Rank 43; likely between #30 and #61 of 258Virus EvolutionOAUniversity of Oxford · United Kingdom | 1.44Q1 | 3.93 0.52 down from 2024 | 320 | 100% | $3,304 | ||
Rank 44; likely between #32 and #62 of 258DiseasesOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.43Q1 | 4.30 0.56 up from 2024 | 645 | 100% | $2,172 | ||
Rank 45; likely between #36 and #55 of 258International Journal of Infectious DiseasesOAElsevier BV · Netherlands | 1.42Q1 | 4.26 0.08 down from 2024 | 1,358 | 100% | $2,900 | ||
Rank 46; likely between #37 and #56 of 258Antimicrobial Agents and ChemotherapyOAAmerican Society for Microbiology · United States | 1.41Q1 | 4.16 0.58 down from 2024 | 1,157 | 100% | — | Rising vs field, 2022–25 | |
Rank 47; likely between #25 and #80 of 258Journal of General VirologyMicrobiology Society · United Kingdom | 1.41Q1 | 3.78 0.76 down from 2024 | 345 | 96% | — | ||
Rank 48; likely between #18 and #108 of 258EpidemiologiaOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.38Q1 | 3.78 1.03 up from 2024 | 137 | 100% | $1,448 | ||
Rank 49; likely between #42 and #57 of 258PathogensOAMultidisciplinary Digital Publishing Institute · Switzerland | 1.38Q1 | 4.00 0.27 up from 2024 | 4,090 | 100% | $2,654 | Rising vs field, 2022–25 | |
Rank 50; likely between #36 and #67 of 258Virologica SinicaElsevier BV · China | 1.36Q1 | 3.77 0.44 up from 2024 | 337 | 100% | $1,500 | Rising vs field, 2022–25 |
48 Infectious Diseases journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1HIV/AIDS - Research and Palliative CareOADove Medical Press · New Zealand+235% vs groupOJR 0.35 → 1.09range +166% to +322%
- 2Access MicrobiologyOAMicrobiology Society · United Kingdom+183% vs groupOJR 0.19 → 0.50range +126% to +254%
- 3Public Health ActionOAInternational Union Against Tuberculosis and Lung Disease+220% vs groupOJR 0.27 → 0.79range +120% to +365%
- 4AIDS Research and TherapyOABioMed Central · United Kingdom+154% vs groupOJR 0.55 → 1.31range +98% to +226%
- 5Journal of the International AIDS SocietyOAInternational AIDS Society · United States+106% vs groupOJR 0.89 → 1.71range +78% to +138%
- 6AIDS CareTaylor & Francis · United Kingdom+102% vs groupOJR 0.37 → 0.70range +74% to +135%
- 7Journal of the International Association of Providers of AIDS Care (JIAPAC)OASAGE Publishing · United States+149% vs groupOJR 0.51 → 1.19range +73% to +259%
- 8The International Journal of Tuberculosis and Lung DiseaseInternational Union Against Tuberculosis and Lung Disease+117% vs groupOJR 0.38 → 0.77range +63% to +189%
- 9Leprosy ReviewOABritish Leprosy Relief Association · United Kingdom+138% vs groupOJR 0.12 → 0.26range +58% to +259%
- 10HIV & AIDS ReviewOATermedia Publishing House · Poland+156% vs groupOJR 0.10 → 0.24range +57% to +318%
- 11AnaerobeElsevier BV · United Kingdom+109% vs groupOJR 0.56 → 1.09range +53% to +186%
- 12African Journal of Laboratory MedicineOAAOSIS · South Africa+121% vs groupOJR 0.25 → 0.52range +52% to +222%
- 13Journal of Clinical Tuberculosis and Other Mycobacterial DiseasesOAElsevier BV · United Kingdom+101% vs groupOJR 0.54 → 1.02range +51% to +167%
- 14The Lancet HIVElsevier BV · Netherlands+93% vs groupOJR 1.56 → 2.82range +48% to +153%
- 15HIV MedicineWiley · United Kingdom+89% vs groupOJR 0.64 → 1.14range +45% to +146%
- 16TuberculosisElsevier BV · United Kingdom+81% vs groupOJR 0.54 → 0.91range +44% to +127%
- 17VirulenceOATaylor & Francis · United States+75% vs groupOJR 1.35 → 2.22range +40% to +118%
- 18Infectious Diseases and TherapyOAAdis, Springer Healthcare · United Kingdom+74% vs groupOJR 1.12 → 1.83range +38% to +120%
- 19International Journal of STD & AIDSSAGE Publishing · United Kingdom+74% vs groupOJR 0.37 → 0.61range +36% to +121%
- 20Medical MycologyOxford University Press · United Kingdom+70% vs groupOJR 0.72 → 1.14range +36% to +113%
No-label zone, -9.1% to +10%Group median changeBar scale -80% to +402% (ratio scale)
12 Infectious Diseases journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1VaccinesOAMultidisciplinary Digital Publishing Institute · Switzerland-37% vs groupOJR 2.01 → 1.19range -43% to -30%
- 2Journal of Medical VirologyWiley · United States-34% vs groupOJR 1.85 → 1.14range -42% to -25%
- 3Future VirologyFuture Medicine · United Kingdom-46% vs groupOJR 0.57 → 0.29range -63% to -23%
- 4Osong Public Health and Research PerspectivesOAElsevier BV · South Korea-49% vs groupOJR 1.14 → 0.55range -67% to -21%
- 5Advances in Infectious DiseasesOAScientific Research Publishing · United States-51% vs groupOJR 0.23 → 0.11range -70% to -18%
- 6Reviews in Medical MicrobiologyLippincott Williams & Wilkins · United Kingdom-50% vs groupOJR 0.23 → 0.11range -70% to -17%
- 7New Microbes and New InfectionsOAElsevier BV · United Kingdom-30% vs groupOJR 0.80 → 0.52range -45% to -11%
- 8Journal of Family Medicine and Primary CareOAMedknow · India-19% vs groupOJR 0.76 → 0.58range -27% to -9.6%
- 9JMIR Public Health and SurveillanceOAJMIR Publications · Canada-26% vs groupOJR 2.54 → 1.76range -40% to -8.2%
- 10Clinical Microbiology and InfectionElsevier BV · United Kingdom-17% vs groupOJR 2.10 → 1.63range -31% to -1.6%
- 11MMWR Morbidity and Mortality Weekly ReportOACenters for Disease Control and Prevention · United States-17% vs groupOJR 7.69 → 5.97range -30% to -1.3%
- 12Infection Disease & HealthElsevier BV · Netherlands-32% vs groupOJR 0.74 → 0.47range -54% to -0.6%
No-label zone, -9.1% to +10%Group median changeBar scale -72% to +255% (ratio scale)
Subfields of Medicine, with Infectious Diseases highlighted.
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
42 additional Infectious Diseases journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 258
- Window papers (baseline)
- 130,899 -3.7% from indicator year 2022
- Median OJR
- 0.75 +24.3% from indicator year 2022
- Rising journals (2025)
- 48
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 70 | 73 | 78 | 82 | 86 | 92 | 95 | 101 | 106 | 110 | 118 | 131 | 144 | 162 | 173 | 182 | 189 | 198 | 210 | 217 | 222 | 234 | 243 | 259 | 263 | 258 | |
| Window papers (baseline) | 18,375 | 21,167 | 22,805 | 24,640 | 25,208 | 28,008 | 31,333 | 35,063 | 38,170 | 42,272 | 46,364 | 49,515 | 52,080 | 54,445 | 58,513 | 62,728 | 67,259 | 69,548 | 70,742 | 70,658 | 72,743 | 100,768 | 135,954 | 162,915 | 153,103 | 130,899 | |
| Median OJR | 0.602 | 0.68 | 0.82 | 0.76 | 0.77 | 0.901 | 0.98 | 0.93 | 1.04 | 0.998 | 1.01 | 0.999 | 0.97 | 0.900 | 0.91 | 0.874 | 0.85 | 0.8699 | 0.8696 | 0.83 | 0.80 | 0.597 | 0.61 | 0.64 | 0.70 | 0.75 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.